Welcome
Support Centre
29 August 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
Optimisation of defibrillation for ventricular fibrillation: the use of low tilt waveforms for the defibrillation of ventricular fibrillation
ISRCTN ISRCTN06531828
DOI 10.1186/ISRCTN06531828
ClinicalTrials.gov identifier
EudraCT number
Public title Optimisation of defibrillation for ventricular fibrillation: the use of low tilt waveforms for the defibrillation of ventricular fibrillation
Scientific title
Acronym N/A
Serial number at source RGHT000386
Study hypothesis Overall survival rates from Ventricular Fibrillation (VF) are currently very poor. A more efficient biphasic defibrillator with novel low-tilt technology could improve the chances of terminating VF early thus increasing the chances of survival. The primary aim of this study is to determine whether the use of a defibrillator with a low-tilt biphasic waveform will improve the success of defibrillation of ventricular fibrillation.
Lay summary Not provided at time of registration
Ethics approval This project has been reviewed and approved by the Office for Research Ethics Committees in Northern Ireland (ORECNI) on the 8th November 2006 (ref: 06/NIR02/108).
Study design Randomised, controlled, safety and feasability study
Countries of recruitment United Kingdom
Disease/condition/study domain Ventricular fibrillation/cardiac arrest
Participants - inclusion criteria All adult patients in cardiac arrest with ventricular fibrillation as the identified rhythm.
Participants - exclusion criteria Patients with existing 'Do not resuscitate' orders.
Anticipated start date 01/12/2006
Anticipated end date 30/11/2007
Status of trial Completed
Patient information material
Target number of participants 110
Interventions This will be a safety and feasibility study which aims to show equivalence in the removal of ventricular fibrillation during cardiac arrests between a novel low-tilt defibrillating device and the standard-tilted defibrillator currently in use in the trust (Philips Agilent Heartstart XL).

Standard-tilted biphasic defibrillators are currently available on all hospital wards, to the cardiac arrest team and the physician-led cardiac ambulance. Randomisation will occur on a daily basis between the novel low-tilt device and the standard-tilted defibrillator. The randomised device will be made available to the cardiac arrest team, in the coronary care unit and also to the physician-led cardiac ambulance.

It will not be possible to blind those staff delivering the defibrillating shocks to the device in use due to their appearances.

Patients found to be in VF will receive treatment according to the resuscitation guidelines issued by the Resuscitation Council (UK) 2005. The standard-tilted device will deliver shocks at 150 J and the low-tilt device 120 J. Following any three unsuccessful shocks, a rescue shock of 200 J will be used from the standard-tilted defibrillator.

All shocks will be delivered via standard self-adhesive pads which have previously been validated for clinical use. Defibrillating shocks will be delivered by a doctor, nurse or resuscitation officer who is fully trained in advanced life support.

The following non-invasive parameters will also be recorded and analysed:
1. Time from collapse to arrival of emergency services
2. Time to first shock
3. Whether Cardio-Pulmonary Resuscitation (CPR) is performed pre-shock
4. Any delays in shock delivery
5. Duration of arrest
6. Drugs administered
7. Patient demographics
7. Aetiology of VF (where possible)

There will be no follow up of any patients. Patients will only be included in the study at the time of required defibrillation.
Primary outcome measure(s) The primary endpoint of the study will be termination of ventricular arrhythmia for greater than or equal to five seconds following shock delivery. This will be determined by analysis of the defibrillator Electrocardiogram (ECG) tracing post-cardiac arrest.
Secondary outcome measure(s) No secondary outcome measures
Sources of funding The Heart Trust Fund (UK)
Trial website
Publications 1. Darragh KM, Doyle C, Walsh SJ, Allen JD, Adgey AAJ, Anderson J, Manoharan G. A novel low tilt biphasic waveform is more efficacious than a standard waveform in the defibrillation of VF. (Abstract) Journal of Electrocardiology, 2007. In Press
2. 2012 results in http://www.ncbi.nlm.nih.gov/pubmed/22579679
Contact name Prof  Jennifer  Adgey
  Address Regional Medical Cardiology Centre
Royal Hospitals
Grosvenor Road
  City/town Belfast
  Zip/Postcode BT12 6BA
  Country United Kingdom
Sponsor Royal Hospitals Trust (UK)
  Address Royal Research Office
Grosvenor Road
  City/town Belfast
  Zip/Postcode BT12 6BA
  Country United Kingdom
  Sponsor website: http://www.belfasttrust.hscni.net/
Date applied 01/05/2007
Last edited 09/07/2013
Date ISRCTN assigned 30/07/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.